Luis Alfonso
Gurpide Ayarra
Consultor Médico
Clínica Universitaria de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (29)
2024
2022
-
Long-Term Outcome of Critically Ill Advanced Cancer Patients Managed in an Intermediate Care Unit
Journal of Clinical Medicine, Vol. 11, Núm. 12, pp. 3472
2019
-
Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Actas Dermo-Sifiliograficas, Vol. 110, Núm. 6, pp. 448-459
-
Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 21, Núm. 5, pp. 556-571
-
Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer
International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001
-
Programmed death–ligand 1 expression on direct Pap-stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens
Cancer Cytopathology, Vol. 127, Núm. 7, pp. 470-480
2017
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
2016
-
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1237-1242
2015
-
Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer
Cancer Cytopathology, Vol. 123, Núm. 4, pp. 230-236
-
Variations in molecular profile in NSCLC can be analyzed using cytological samples: Development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient
International Journal of Surgical Pathology, Vol. 23, Núm. 2, pp. 111-115
2014
-
Erratum to: Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer
European Journal of Nuclear Medicine and Molecular Imaging
-
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma
PLoS ONE, Vol. 9, Núm. 1
-
Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy
PLoS ONE, Vol. 9, Núm. 2
-
Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, Núm. 11, pp. 2058-2065
2013
-
Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study
Thrombosis Research, Vol. 132, Núm. 6, pp. 666-670
2011
-
Assessment of epidermal growth factor receptor and krasmutation status in cytological stained smears of non-small celllung cancer patients: Correlation with clinical outcomes
Oncologist, Vol. 16, Núm. 6, pp. 877-885
-
Brain metastases from lung cancer responding to erlotinib: The importance of EGFR mutation
European Respiratory Journal, Vol. 37, Núm. 3, pp. 624-631
2009
-
Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
British Journal of Cancer, Vol. 101, Núm. 11, pp. 1876-1883
-
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119
-
Large cell carcinoma of the lung: An endangered species?
Applied Immunohistochemistry and Molecular Morphology, Vol. 17, Núm. 5, pp. 383-392